Our pipeline
Home / Our therapy areas / Our pipeline
Latest quarterly updates
澳门葡京赌博游戏的产品线在临床开发的不同阶段形成了强大的研究性治疗组合.
172
14
1
第三阶段/LCM项目:指的是第二/第三阶段的关键资产, 或者已经提交监管部门批准的, 并且可能包括现在在一个或多个主要市场推出的资产(在所有适用的主要市场推出时删除).
Oncology (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
心血管、肾脏及新陈代谢(截至2023年7月28日)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Respiratory & Immunology (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Vaccine & Immune therapies (as of 28 July 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Other (as of 28 July 2023)
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Removed since last quarter
Veeva ID: Z4-57208
Date of preparation: August 2023